DE69533463D1 - Peptid-Inhibitoren von p33cdk2 und p34cdc2 Zellzyklus regulierenden Kinasen und humanem Papillomavirus E7 Onkoprotein - Google Patents

Peptid-Inhibitoren von p33cdk2 und p34cdc2 Zellzyklus regulierenden Kinasen und humanem Papillomavirus E7 Onkoprotein

Info

Publication number
DE69533463D1
DE69533463D1 DE69533463T DE69533463T DE69533463D1 DE 69533463 D1 DE69533463 D1 DE 69533463D1 DE 69533463 T DE69533463 T DE 69533463T DE 69533463 T DE69533463 T DE 69533463T DE 69533463 D1 DE69533463 D1 DE 69533463D1
Authority
DE
Germany
Prior art keywords
human papillomavirus
p33cdk2
p34cdc2
oncoprotein
cell cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69533463T
Other languages
English (en)
Other versions
DE69533463T2 (de
Inventor
Kevin R Webster
Kevin G Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE69533463D1 publication Critical patent/DE69533463D1/de
Publication of DE69533463T2 publication Critical patent/DE69533463T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736Retinoblastoma protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69533463T 1994-02-08 1995-02-07 Peptid-Inhibitoren von p33cdk2 und p34cdc2 Zellzyklus regulierenden Kinasen und humanem Papillomavirus E7 Onkoprotein Expired - Fee Related DE69533463T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/193,977 US5625031A (en) 1994-02-08 1994-02-08 Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US193977 1994-02-08

Publications (2)

Publication Number Publication Date
DE69533463D1 true DE69533463D1 (de) 2004-10-14
DE69533463T2 DE69533463T2 (de) 2005-09-22

Family

ID=22715824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533463T Expired - Fee Related DE69533463T2 (de) 1994-02-08 1995-02-07 Peptid-Inhibitoren von p33cdk2 und p34cdc2 Zellzyklus regulierenden Kinasen und humanem Papillomavirus E7 Onkoprotein

Country Status (7)

Country Link
US (1) US5625031A (de)
EP (1) EP0666270B1 (de)
JP (1) JPH07316196A (de)
AT (1) ATE275578T1 (de)
CA (1) CA2140379A1 (de)
DE (1) DE69533463T2 (de)
ES (1) ES2227538T3 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090618A (en) 1996-10-07 2000-07-18 Arch Development Corporation DNA constructs and viral vectors comprising a smooth muscle promoter
US7169764B1 (en) 1995-10-05 2007-01-30 Arch Development Corporation Promoter for smooth muscle cell expression
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
DE19653445C1 (de) * 1996-03-26 1997-12-11 Razvan T Dr Med Radulescu Peptide mit antineoplastischen Eigenschaften
ATE229977T1 (de) * 1996-03-26 2003-01-15 Razvan T Radulescu Peptide mit antiproliferativen eigenschaften
AU3300397A (en) * 1996-06-03 1998-01-05 St. Jude Children's Research Hospital Cyclin-c variants, and diagnostic and therapeutic uses thereof
US6075123A (en) * 1996-06-03 2000-06-13 St. Jude Children's Research Hospital Cyclin-C variants, and diagnostic and therapeutic uses thereof
US6297357B1 (en) 1997-08-21 2001-10-02 Thomas Jefferson University prb2/p130 peptide inhibitors of cdk2 kinase activity
ATE332896T1 (de) 1997-10-27 2006-08-15 Agouron Pharma 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen
US6727079B1 (en) * 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
ATE235509T1 (de) * 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
ES2296615T3 (es) 1999-04-08 2008-05-01 Antisoma Research Limited Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina.
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6200746B1 (en) * 1999-08-25 2001-03-13 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US6641994B2 (en) 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
ATE343562T1 (de) * 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
CN1323894A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人p34cdc2相关蛋白激酶9和编码这种多肽的多核苷酸
KR20010110855A (ko) * 2000-06-08 2001-12-15 복성해 자궁경부암 항암제 및 세포사멸조절인자 검색방법
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
DE60112942T2 (de) * 2000-06-30 2006-06-22 Elan Pharmaceuticals, Inc., South San Francisco Verbindungen zur behandlung der alzheimerischen krankheit
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
MXPA03001189A (es) 2000-08-09 2004-05-14 Agouron Pharma Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
ATE295354T1 (de) 2000-08-18 2005-05-15 Agouron Pharma Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
BR0116330A (pt) * 2000-12-20 2004-02-25 Novartis Ag Inibidores da interação e2f-1/ciclina para terapia de câncer
MXPA04000140A (es) * 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
KR100858262B1 (ko) 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Cdk2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
US8158586B2 (en) 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7470670B2 (en) 2006-10-17 2008-12-30 Sbarro Health Research Organization, Inc. Peptide inhibitors of cyclin-dependent kinase activity and uses thereof
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
WO2014157965A1 (ko) * 2013-03-27 2014-10-02 재단법인 아산사회복지재단 P34의 발현 억제제 또는 활성 억제제를 유효성분으로 포함하는 암의 치료 또는 전이 억제용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398955B1 (de) * 1988-01-21 1998-07-08 MASSACHUSETTS EYE & EAR INFIRMARY Diagnose von retinoblastoma
DE69233399T2 (de) * 1991-09-20 2005-08-04 Fred Hutchinson Cancer Research Center, Seattle Menschliches cyclin e

Also Published As

Publication number Publication date
JPH07316196A (ja) 1995-12-05
US5625031A (en) 1997-04-29
EP0666270A2 (de) 1995-08-09
ATE275578T1 (de) 2004-09-15
CA2140379A1 (en) 1995-08-09
EP0666270A3 (de) 1996-02-07
EP0666270B1 (de) 2004-09-08
DE69533463T2 (de) 2005-09-22
ES2227538T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
DE69533463D1 (de) Peptid-Inhibitoren von p33cdk2 und p34cdc2 Zellzyklus regulierenden Kinasen und humanem Papillomavirus E7 Onkoprotein
WO1995033819A3 (en) Cdk4 (cyclin dependent kinase 4) binding proteins
ATE310812T1 (de) Derivate von zinkfingerproteinen und methoden
PT888353E (pt) Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
DE69433406D1 (de) Antikörper gegen cd40
DE60025037D1 (de) "functional genomics" unter verwendung von zink finger proteinen
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ZA988797B (en) Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds.
DE60041452D1 (de) CpG REZEPTOR (CpG-R) UND DARAUF BEZOGENE METHODEN
NO980905D0 (no) Antagonister av den oncogeniske aktivitet av proteinet mdm2 samt anvendelsen derav ved behandling av cancer
WO2001014584A3 (en) Methods of identifying anti-viral agents
TR199900903T2 (xx) Bir t�m�r nekroz fakt�r� ailesine ili�kin protein
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
AU9550198A (en) Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DE69836758D1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
ATE305037T1 (de) Peptide, die fähig sind die sh3-domäne des gap- proteins zu binden, ihre kodierende dns, ihre zubereitung und verwendung
ATA192799A (de) Neue verwendung von antikörpern als impfstoffe
DE69804125T2 (de) Verwendung von immunomodulatoren
BR9710919A (pt) Proteina purificada sr-p70
DE50002164D1 (de) Peptide zur inhibierung von hpv e6-proteinen
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
WO2003073062A3 (en) Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee